Log in

Zogenix Stock Forecast, Price & News

+0.48 (+2.28 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $21.56
50-Day Range
MA: $20.62
52-Week Range
Now: $21.56
Volume319,509 shs
Average Volume1.11 million shs
Market Capitalization$1.20 billion
P/E RatioN/A
Dividend YieldN/A
Zogenix, Inc., a pharmaceutical company, develops and commercializes transformative therapies to enhance the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS); and which is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It also developing MT1621, an investigational deoxynucleoside substrate enhancement therapy for the treatment of inherited mitochondrial DNA depletion disorder thymidine kinase 2 deficiency (TK2d). The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Read More
Zogenix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.69 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ZGNX



Sales & Book Value

Annual Sales$3.65 million
Book Value$5.54 per share


Net Income$-419,500,000.00
Net Margins-8,758.48%


Market Cap$1.20 billion
Next Earnings Date3/1/2021 (Estimated)
+0.48 (+2.28 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

How has Zogenix's stock price been impacted by Coronavirus (COVID-19)?

Zogenix's stock was trading at $22.69 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZGNX stock has decreased by 5.0% and is now trading at $21.56.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Zogenix?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zogenix

What stocks does MarketBeat like better than Zogenix?

Wall Street analysts have given Zogenix a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zogenix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Zogenix's next earnings date?

Zogenix is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Zogenix

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) released its earnings results on Monday, November, 9th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.01) by $0.07. The company had revenue of $2.86 million for the quarter, compared to the consensus estimate of $2.35 million. Zogenix had a negative net margin of 8,758.48% and a negative return on equity of 53.91%. The firm's quarterly revenue was up 354.0% compared to the same quarter last year. During the same period last year, the company posted ($6.75) EPS.
View Zogenix's earnings history

What price target have analysts set for ZGNX?

11 equities research analysts have issued 12-month price objectives for Zogenix's shares. Their forecasts range from $27.00 to $78.00. On average, they anticipate Zogenix's share price to reach $53.50 in the next year. This suggests a possible upside of 148.1% from the stock's current price.
View analysts' price targets for Zogenix

Who are some of Zogenix's key competitors?

What other stocks do shareholders of Zogenix own?

Who are Zogenix's key executives?

Zogenix's management team includes the following people:
  • Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 61, Pay $867.95k)
  • Mr. Michael P. Smith, Exec. VP, CFO & Treasurer (Age 52, Pay $573.34k)
  • Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 58, Pay $582.08k)
  • Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 56, Pay $568.5k)
  • Mr. Ashish M. Sagrolikar, Exec. VP & Chief Commercial Officer (Age 53, Pay $541.24k)
  • Mr. Jeff D. Durflinger, VP of Technical Operations & Product Supply (Age 59)
  • Ms. Shawnte M. Mitchell, Exec. VP, Gen. Counsel & Sec. (Age 42)
  • Melinda Baker, Sr. Director of Corp. Communications
  • Mr. Bret E. Megargel, VP of Corp. Devel. (Age 51)
  • Mr. Stephen H. Jenner, VP of Marketing (Age 52)

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

Who are Zogenix's major shareholders?

Zogenix's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.23%), Federated Hermes Inc. (4.41%), State Street Corp (2.30%), Vivo Capital LLC (1.47%), Point72 Asset Management L.P. (1.27%) and Emerald Advisers LLC (1.20%). Company insiders that own Zogenix stock include Ashish M Sagrolikar, Cam L Garner, Gail M Farfel, James B Breitmeyer, Mark C Wiggins, Michael P Smith, Renee P Tannenbaum, Roger Hawley and Stephen J Farr.
View institutional ownership trends for Zogenix

Which institutional investors are selling Zogenix stock?

ZGNX stock was sold by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P., Emerald Mutual Fund Advisers Trust, BlackRock Inc., First Midwest Bank Trust Division, ExodusPoint Capital Management LP, UBS Asset Management Americas Inc., WINTON GROUP Ltd, and Squarepoint Ops LLC. Company insiders that have sold Zogenix company stock in the last year include James B Breitmeyer, Michael P Smith, Renee P Tannenbaum, and Stephen J Farr.
View insider buying and selling activity for Zogenix

Which institutional investors are buying Zogenix stock?

ZGNX stock was bought by a variety of institutional investors in the last quarter, including Blackstone Group Inc, Point72 Asset Management L.P., Voloridge Investment Management LLC, Federated Hermes Inc., Vivo Capital LLC, Soros Fund Management LLC, Morgan Stanley, and Engineers Gate Manager LP. Company insiders that have bought Zogenix stock in the last two years include Ashish M Sagrolikar, Cam L Garner, and Mark C Wiggins.
View insider buying and selling activity for Zogenix

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $21.56.

How big of a company is Zogenix?

Zogenix has a market capitalization of $1.20 billion and generates $3.65 million in revenue each year. The company earns $-419,500,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis. Zogenix employs 141 workers across the globe.

What is Zogenix's official website?

The official website for Zogenix is www.zogenix.com.

How can I contact Zogenix?

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.